ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1882

Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations

Philipp Bosch1, Milena Bond2, Christian Dejaco3, Cristina Ponte4, Sarah Mackie5, Louise Falzon6, Wolfgang Schmidt7 and Sofia Ramiro8, 1Medical University of Graz, Graz, Austria, 2Azienda sanitaria dell'Alto Adige, Merano, Italy, 3Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, 4Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6University of Sheffield, Sheffield, United Kingdom, 7Immanuel Krankenhaus Berlin, Berlin, Germany, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: ACR Convergence 2023

Keywords: giant cell arteritis, Magnetic resonance imaging (MRI), Takayasu.s arteritis, Ultrasound, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1862–1894) Imaging of Rheumatic Diseases Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Since the development of the EULAR recommendations for the use of imaging in large vessel vasculitis (LVV) in 2017, new data has emerged in the field of imaging techniques and their application in the diagnosis and follow-up of patients with giant cell arteritis (GCA) and Takayasu arteritis (TAK).The objective of this review was to summarize the evidence on different imaging techniques for diagnosis, monitoring, and outcome prediction in LVV in order to inform a EULAR task force updating the recommendations for imaging in LVV.

Methods: Systematic literature review (SLR) on studies published between 2017-2022 on ultrasound (US), magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET)-CT/MRI and fluorescein angiography in patients with LVV (PROSPERO registration CRD42022360545). Eligible study designs included randomized controlled trials and observational studies but excluded case-controlled studies. Two reviewers independently performed data extraction, synthesis, and risk of bias assessment. For studies on diagnosis, meta-analyses were performed using data from both the original and updated SLR whenever possible. Pooled sensitivities and specificities were obtained by fitting random effects models for all studies and for studies with low risk of bias separately. Meta-analyses were performed in R version 4.2.1. using the “lme4” package. The description of observations without inferences and the heterogeneity of reported data precluded any meta-analysis for outcome prediction or monitoring.

Results: A total of 4696 references were identified. Thirty-eight studies on GCA (n=32), TAK (n=2), and GCA and TAK (n=4) were included through the update, adding up to eighty-one studies from both SLRs. Pooled sensitivities and specificities for US, MRI and PET-CT using a clinical diagnosis of GCA as the reference standard are depicted in table 1. No studies on the diagnostic value of imaging techniques were found for TAK. The US evaluation of patients with suspected GCA, including the assessment of both cranial and extracranial vessels, showed a higher pooled sensitivity (95%CI) (89% [73%-96%] vs 70% [59%-79%]) and similar specificity (95%CI) (91% [83%-95%] vs 91% [84%-94%]) compared to only including cranial vessels. Studies on outcome prediction (n=5) and monitoring (n=10) reported change of signs of vasculitis along with disease activity and proposed composite scores comprising several vessel territories for US, MRI and PET-CT.

Conclusion: US, MRI and PET-CT revealed a good performance for the diagnosis of GCA. Assessing both cranial and extracranial vessels with US leads to a higher pooled sensitivity with a similar pooled specificity compared to an assessment limited to cranial vessels.

Supporting image 1

Table 1. Pooled sensitivities and specificities of diagnostic studies on GCA with clinical diagnosis as reference standard
GCA, giant cell arteritis; MRI, magnetic resonance imaging; PET-CT, positron emission tomography – computed tomography; US, ultrasound


Disclosures: P. Bosch: Janssen, 6, 12, Congress fees, Pfizer, 5; M. Bond: AbbVie/Abbott, 5; C. Dejaco: AbbVie/Abbott, 1, 5, 6, Eli Lilly, 6, Galapagos Pharma, 1, 6, Janssen, 1, 6, Novartis, 1, 6, Pfizer, 6, Sparrow, 1; C. Ponte: None; S. Mackie: AbbVie/Abbott, 2, AstraZeneca, 2, GlaxoSmithKlein(GSK), 3, 12, Investigator, National Institute for Health and Care Research, 5, 12, investigator on STERLING-PMR trial, funded by NIHR; patron of the charity PMRGCAuk, Pfizer, 2, 6, Roche, 2, 6, 12, Support from Roche/Chugai to attend EULAR2019 in person, Sanofi, 2, 12, Investigator, Sparrow, 12, Investigator, UCB and Novartis, 6, Vifor, 6; L. Falzon: None; W. Schmidt: AbbVie/Abbott, 2, 5, 6, Amgen, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Chugai, 2, 6, Eli Lilly, 2, GlaxoSmithKlein(GSK), 5, 6, Johnson & Johnson, 2, Medac, 2, Novartis, 2, 5, 6, Pfizer, 2, Roche, 2, 6, Sanofi, 2, 5, 6, UCB, 2; S. Ramiro: AbbVie, 2, 5, Eli Lilly, 2, Galapagos, 5, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, UCB Pharma, 2, 5.

To cite this abstract in AMA style:

Bosch P, Bond M, Dejaco C, Ponte C, Mackie S, Falzon L, Schmidt W, Ramiro S. Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/imaging-in-diagnosis-monitoring-and-outcome-prediction-of-large-vessel-vasculitis-a-systematic-literature-review-informing-the-2023-update-of-the-eular-recommendations/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/imaging-in-diagnosis-monitoring-and-outcome-prediction-of-large-vessel-vasculitis-a-systematic-literature-review-informing-the-2023-update-of-the-eular-recommendations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology